Patents Assigned to ONXEO
  • Oral formulations of belinostat
    Patent number: 11266614
    Abstract: The present application concerns new formulations of belinostat suitable for oral administration, their process of preparation, the pharmaceutical compositions comprising said formulations and their uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 8, 2022
    Assignee: ONXEO
    Inventors: Perrine Pivette, Caroline Lemarchand, Ian Yates, Corey Bloom
  • Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
    Patent number: 11162095
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 2, 2021
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • Treatment of cancer by systemic administration of Dbait molecules
    Patent number: 10821128
    Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 3, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Marie Dutreix, Nathalie Berthault
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10765758
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 8, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
    Patent number: 10563197
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: February 18, 2020
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10363317
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: July 30, 2019
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Nanoparticles loaded with chemotherapeutic antitumoral drug
    Patent number: 9763874
    Abstract: The invention relates to new therapeutic approaches for treating cancer, in particular hepatocellular carcinoma, with Nanoparticules loaded with a chemotherapeutic antitumoral agent. In particular, it relates to the treatment of cancer by administration of said Nanoparticules by intravenous infusion for at least 2 hours in order to prevent toxicological side effects and increase the benefit/risk ratio of the treatment.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 19, 2017
    Assignee: Onxeo S.A.
    Inventors: Emilia Pisani, Sophie Lebel-Binay, Valérie Polard
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9687557
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 27, 2017
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers
    Patent number: 9192599
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: November 24, 2015
    Assignee: Onxeo S.A.
    Inventors: Pierre Attali, Caroline Lemarchand, Vanessa Roulet, Claire Scheuir, Lorraine Zakin
  • Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers
    Patent number: 9089559
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: July 28, 2015
    Assignee: ONXEO S.A.
    Inventors: Pierre Attali, Caroline Lemarchand, Vanessa Roulet, Claire Scheuir, Lorraine Zakin